Ginkgo Bioworks Holdings, Inc. (NYSE: DNA)

Ginkgo Bioworks Holdings, Inc. is a biotechnology company that provides cell engineering and biosecurity services through an integrated platform designed to make biology easier to engineer. The company’s mission is to enable customers to program biology for the development of new therapeutics vaccines agricultural inputs industrial chemicals and biosecurity solutions. Its platform combines laboratory automation hardware software data assets and scientific expertise to deliver R&D services tools and analytics that improve with each project. Ginkgo serves customers across medicine agriculture industrial biotech and government sectors by offering customizable solutions and standardized tools that reduce development time cost and risk.

Revenue is generated primarily from cell engineering solutions which include service fees for R&D projects fees for cell engineering tools such as RAC systems and Datapoints services and support fees for automation and data offerings. Fees for cell engineering programs are often structured as fixed payments for defined scope of work with additional milestone payments tied to technical achievements. The company also participates in value share arrangements receiving royalties milestone payments or equity interests that provide upside when customer products succeed. Biosecurity revenue comes from fees for Canopy biomonitoring programs Horizon analytics services and related support while the segment benefits from scale driven improvements in data collection and analysis.

The company operates through the following segments: Cell Engineering and Biosecurity. Each segment is defined by the type of service offered and the primary customer groups it serves.

• Cell Engineering provides research and development services and tools that help customers discover optimize and manufacture biotechnology products across medicine agriculture industrial biotech and government applications. Services include the Autonomous Lab for high throughput data generation RAC systems for flexible automation Datapoints for specialized data sets AI models for predictive design and solution offerings such as protein engineering genetic medicines crop nutrition crop protection plant traits small molecules enzymes and fermentation scale up. Revenue is derived from service fees support fees and value share arrangements that align the company’s earnings with customer success.

• Biosecurity offers two core offerings Canopy which generates high value genomic data from strategically positioned nodes such as airports and borders through end to end biomonitoring programs and Horizon which provides global data analytics and insights for detecting monitoring and predicting biological threats. Canopy involves program design sample collection sequencing bioinformatics and delivery of insights while Horizon integrates early detection genomic surveillance and digital biothreat intelligence into a unified analytics platform. The segment serves primarily government customers and earns revenue from program fees data services insights and support while benefiting from platform improvements that increase with scale.

Ginkgo Bioworks Holdings, Inc. occupies a distinctive position in the biotechnology industry by combining laboratory automation software data assets and scientific expertise into a single platform that improves with scale. The company competes against internal R&D departments contract research organizations life science tools companies and vertically focused platforms such as AbCellera Codexis Senti Bio and WuXi biologics. Competitive advantages include the ability to generate larger and higher quality data sets through the Autonomous Lab the reuse of data and host cell assets across projects and the integration of AI driven models that accelerate design cycles. In biosecurity Ginkgo leverages a global network of detection nodes and partnerships with governments and multilaterals to provide end to end surveillance that few competitors can match. These strengths allow Ginkgo to offer customers faster development timelines lower experimental costs and higher probability of success compared with traditional in house efforts.

Ginkgo Bioworks Holdings, Inc. serves a diverse customer base that includes government agencies pharmaceutical and biotechnology companies agricultural firms and industrial biotech enterprises. Specific customers mentioned in the filing include Bayer Crop Sciences for crop nutrition projects Virica Biotech for AAV manufacturing optimization and pharmaceutical leaders such as Biogen Novo Nordisk Vertex Regeneron and Bayer. The company also works with academic research institutions and various specialty chemical and specialty materials companies to develop enzymes small molecules and other biobased products. Government customers span federal state and local agencies in the United States and abroad that rely on Ginkgo for biosecurity monitoring pathogen detection and pandemic preparedness initiatives. Pharmaceutical and biotech clients use the platform to advance drug discovery optimize manufacturing processes and create novel biologics gene therapies and vaccines. Agricultural partners seek Ginkgo’s expertise to improve crop nutrition enhance soil health develop biological pesticides and create sustainable farming solutions. Industrial biotech firms engage the company to produce enzymes chemicals and specialty materials through engineered microbial processes.